Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Episode Summary

Executive Summary: Andrew Huberman and Dr. Craig Conover discuss peptide biology as a practical, rapidly evolving toolset for mental health, physical health, and performance. They cover GLP-1s, BPC-157 alternatives, growth-hormone secretagogues, sleep peptides, NAD, methylene blue, methylated B vitamins, and the importance of physician oversight, compounding-pharmacy sourcing, and cautious dosing amid shifting FDA regulation.

Main Topics: What peptides are and why they matter (Priority: 5/5): Conover defines peptides as short amino-acid chains and frames them as a large, underused therapeutic class that can influence inflammation, recovery, sleep, metabolism, and performance without directly replacing hormones. GLP-1 agonists for weight loss and metabolic health (Priority: 5/5): The discussion covers semaglutide/tirzepatide, off-label prescribing, microdosing to reduce muscle loss and side effects, and the idea that weight loss can improve motivation, cognition, and inflammation. BPC-157, PDA, and tissue repair/inflammation (Priority: 5/5): They discuss BPC-157’s anti-inflammatory and recovery uses, the FDA’s removal of it from compounding, and pentadeca arginate (PDA) as a close substitute used clinically for similar effects. Growth-hormone secretagogues and sleep/performance (Priority: 4/5): Conover explains sermorelin, tesamorelin, ipamorelin, hexarelin, GHRP-6, CJC1295, and MK-677, emphasizing flavor-specific effects such as sleep support, appetite stimulation, endurance, and muscle gain. Sleep peptides and REM enhancement (Priority: 4/5): Pinealine plus glycine is presented as a notable tool for improving REM sleep and overall sleep quality, with the claim that benefits may persist beyond the nights it is taken. NAD, methylene blue, and mitochondrial support (Priority: 4/5): The conversation highlights NAD infusions/injections as highly impactful for energy, mood, cognition, and recovery, and methylene blue as a mitochondrial/cognitive enhancer with oral and IV uses. Safety, sourcing, and FDA/compounding issues (Priority: 5/5): A major theme is the risk of gray-market peptides, endotoxin contamination, and the value of board-certified physicians and regulated compounding pharmacies; they also debate FDA overreach versus safety concerns.

Key Arguments: Peptides are short amino-acid chains and can be used therapeutically to influence multiple biological pathways without directly shutting down endogenous hormone production. GLP-1 drugs can be useful when microdosed and paired with resistance training and adequate protein to reduce rapid weight loss and muscle loss. Weight loss can improve motivation, cognition, inflammation, and adherence to healthier behaviors, making it a gateway to broader lifestyle change. BPC-157 appears strongly anti-inflammatory and recovery-promoting, but because legitimate access has been restricted, PDA is a promising substitute. Growth-hormone secretagogues differ meaningfully: ipamorelin is cleaner and more sleep-oriented, GHRP-6 is more appetite- and mass-oriented, and tesamorelin is useful for visceral fat. Pinealine plus glycine may substantially increase REM sleep and improve sleep quality, with possible lasting effects beyond the dosing night. NAD is the single most impactful intervention Conover has used clinically, with broad benefits for mood, cognition, energy, and recovery. Compounding pharmacies are presented as the safest legitimate source for injectable peptides because they are regulated, tested for purity, and can customize dosing. Gray-market and research-only peptide products may contain contaminants such as endotoxin/LPS and pose serious safety risks. The FDA’s peptide restrictions are framed as a mix of legitimate safety oversight and possible overreach that may also benefit pharmaceutical commercialization.

Data Points: Peptide length threshold: 40 amino acids or less = peptide; 41 or more = protein - Conover’s basic definition of peptides Estimated number of peptides made by the body: 300,000 - Conover’s estimate of endogenous peptide diversity Therapeutic peptides used over the years: ~150 - Conover’s estimate of peptides used clinically GLP-1 weight-loss rise: A couple of years - He says the weight-loss use of GLP-1s accelerated recently Weight-loss rate target on GLP-1s: 2 pounds/week or less - Microdosing strategy to reduce muscle loss BPC-157 starting dose: 500 micrograms/day - Conover’s conservative starting protocol BPC-157 upper dose used clinically: 5,000 micrograms/day - Observed higher-dose use in practice BPC schedule: 5 days on, 2 days off - Common dosing rhythm used in clinic PDA starting dose: 250–500 micrograms/day - Suggested substitute for BPC-157 PDA typical dose used: 500 micrograms daily - Conover’s current clinical practice Ipamorelin dose: 100 micrograms - Typical bedtime dose; max dose mentioned for receptor binding Tesamorelin dose: 2 milligrams (2,000 micrograms) - Ideal dose cited for visceral fat reduction Sermorelin dose range: 200–3,000 micrograms - Broad dosing range depending on goals Hexarelin dose: 100 micrograms - Typical morning dose for energy/endurance Methylene blue dose: 10 milligrams orally - Suggested cognitive-support dose Methylene blue IV dose in office: Up to 50 milligrams - Used during IV treatments NAD IV loading dose: 750 milligrams - Conover’s preferred IV dose NAD maintenance frequency: Once per month - Typical follow-up after loading NAD subcutaneous dose: 100 milligrams - Used during the pandemic when infusions were less feasible NAD loading protocol: 5 treatments in 10 days - Conover’s clinic protocol Original NAD addiction protocol: 3,000 milligrams over 10 days - Historical Mexico protocol Glycine oral starting dose: 3–5 grams at bedtime - Used for calming and sleep support Glycine escalation dose: 10 grams - If lower dose is ineffective CoQ10 dose: 200 milligrams/day - Conover’s preferred morning supplement dose CoQ10 safety ceiling mentioned: Up to 2,400 milligrams/day - He cites studies showing no harmful effects Methylene blue urine discoloration duration: About 24 hours - Expected sign of oral dosing Pinealine effect: Approximately doubled REM sleep - Huberman’s self-experiment using sleep tracking FDA peptide action date referenced: October 2023 - When many peptides were placed on a category-2 compounding restriction list

Pivotal Quotes: "I want to help people win the race first, which then helps them motivate to train for the next race." — Dr. Craig Conover: Explaining his philosophy for using GLP-1s and other interventions to create momentum for behavior change "No good has ever come from a negative thought." — Dr. Craig Conover: His view on mindset, positivity, and health outcomes "If I had to pick one thing for people, engaging in NAD would be it." — Dr. Craig Conover: His strongest single recommendation based on clinical experience

Implications: The episode argues that peptides may become a major bridge between lifestyle change and hormone therapy, but only if sourced safely and used with expert guidance. It also suggests the FDA, compounding pharmacies, and pharma will increasingly shape access, cost, and innovation.